There were 1,671 press releases posted in the last 24 hours and 447,269 in the last 365 days.

Contact

Please use this form to send email to PR contact of this press release:
Communiqué : Résultats de phase II montrent que le rilzabrutinib permet de réduire rapidement la sévérité des démangeaisons causées par l’urticaire chronique spontanée et d’améliorer significativement l’activité de la maladie chez…

TO:



FROM:

Please check your email address!

Please, do not fill this field.

Please, do not change this field.

Please, do not fill if your javascript is turned off.

captcha image